Moderna Aktie News

U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the European Union renegotiated its vaccine supply agreement with Pfizer and BioNTech.

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you.

A few years ago, Moderna (MRNA 2.77%) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw its stock price skyrocket.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.